Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Randomized Controlled Clinical Study of Neoadjuvant Combination of Axitinib Plus PD-1 Monoclonal Antibody to Improve Disease Free Survival of Patients With Renal Cell Carcinoma

NCT05738694 is registered in ClinicalTrials.gov with ZHOU FANGJIAN as lead sponsor.

NCT NCT05738694
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05738694 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Randomized Controlled Clinical Study of Neoadjuvant Combination of Axitinib Plus PD-1 Monoclonal Antibody to Improve Disease Free Survival of Patients With Renal Cell Carcinoma
Lead sponsor
ZHOU FANGJIAN
Phase
Phase 3
Overall status
Recruiting
Start date
April 19, 2023
Completion date
December 31, 2027
Enrollment
298 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

neoadjuvant, renal cell carcinoma